Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Amylyx Pharmaceuticals, Inc. (AMLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.77 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 196.69K shares, a 22.66% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.57M shares, a 24.74% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 49.10K shares, a 211.77% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 107.60K shares, a 3370.97% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.47M shares, a 19.47% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.07M shares, a 7.26% increase from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.86M shares, a 32.40% decline from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 4.24M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 196.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.77M shares 10-Q · filed 2026-08-06 | 2.82M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.93M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.57M shares 10-Q · filed 2026-05-07 | 2.62M shares derived: sum of 2 quarters · filed 2026-05-07 | 2.73M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.99M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 49.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 156.70K shares derived: sum of 2 quarters · filed 2026-03-03 | 411.03K shares derived: sum of 3 quarters · filed 2026-03-03 | 2.47M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 107.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 361.93K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.43M shares 10-Q · filed 2025-11-06 | 2.44M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 254.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.32M shares 10-Q · filed 2025-08-07 | 2.33M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.34M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.06M shares 10-Q · filed 2025-05-08 | 2.08M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.08M shares derived: sum of 3 quarters · filed 2025-05-08 | 3.78M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 15.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 18.85K shares derived: sum of 2 quarters · filed 2025-03-04 | 1.71M shares derived: sum of 3 quarters · filed 2025-03-04 | 3.07M shares 10-K · filed 2025-03-04 |
| 2024-09-30 | 3.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.70M shares derived: sum of 2 quarters · filed 2024-11-07 | 3.06M shares 10-Q · filed 2024-11-07 | 3.36M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 1.70M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 3.05M shares 10-Q · filed 2024-08-08 | 3.36M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.52M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.36M shares 10-Q · filed 2024-05-09 | 1.67M shares derived: sum of 2 quarters · filed 2024-05-09 | 1.82M shares derived: sum of 3 quarters · filed 2024-05-09 | 2.12M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 307.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 465.64K shares derived: sum of 2 quarters · filed 2024-02-22 | 759.07K shares derived: sum of 3 quarters · filed 2024-02-22 | 2.86M shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 158.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 451.94K shares derived: sum of 2 quarters · filed 2023-11-09 | 2.56M shares 10-Q · filed 2023-11-09 | 2.83M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 293.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 2.40M shares 10-Q · filed 2023-08-10 | 2.67M shares derived: sum of 3 quarters · filed 2023-08-10 | 2.76M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 2.11M shares 10-Q · filed 2023-05-11 | 2.37M shares derived: sum of 2 quarters · filed 2023-05-11 | 2.47M shares derived: sum of 3 quarters · filed 2023-05-11 | 2.69M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 269.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 365.20K shares derived: sum of 2 quarters · filed 2023-03-13 | 579.82K shares derived: sum of 3 quarters · filed 2023-03-13 | 4.24M shares 10-K · filed 2023-03-13 |
| 2022-09-30 | 96.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 310.82K shares derived: sum of 2 quarters · filed 2022-11-10 | 3.97M shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 214.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 3.87M shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 3.66M shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |